@inproceedings{inproceedings, title  = {{A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-Guerin (BCG) therapy}},

 url = {{}},

 year = {{2020}},

 month = {{1}},

 author = {{Steinberg GD and Palou-Redorta J and Gschwend JE and Ben T and Loriot Y and Daneshmand S and Roupret M and Santiago-Walker AE and Switzky JC and Major C and Baig M et al}},

 volume = {{38}},

 journal = {{JOURNAL OF CLINICAL ONCOLOGY}},

 issue = {{6}},

 note = {{Accessed on 2024/10/23}}}